Acetic acid-guided biopsies in Barrett's surveillance for neoplasia detection versus non-targeted biopsies (Seattle protocol): A feasibility study for a randomized tandem endoscopy trial. The ABBA study

Fergus Chedgy, Carole Fogg, Kesavan Kandiah, Hugh Barr, Bernard Higgins, Mimi McCord, Ann Dewey, John De Caestecker, Lisa Gadeke, Clive Stokes, David Poller, Gaius Longcroft-Wheaton, Pradeep Bhandari, Fergus Chedgy, Carole Fogg, Kesavan Kandiah, Hugh Barr, Bernard Higgins, Mimi McCord, Ann Dewey, John De Caestecker, Lisa Gadeke, Clive Stokes, David Poller, Gaius Longcroft-Wheaton, Pradeep Bhandari

Abstract

Background and study aims: Barrett's esophagus is a potentially pre-cancerous condition, affecting 375,000 people in the UK. Patients receive a 2-yearly endoscopy to detect cancerous changes, as early detection and treatment results in better outcomes. Current treatment requires random mapping biopsies along the length of Barrett's, in addition to biopsy of visible abnormalities. As only 13 % of pre-cancerous changes appear as visible nodules or abnormalities, areas of dysplasia are often missed. Acetic acid chromoendoscopy (AAC) has been shown to improve detection of pre-cancerous and cancerous tissue in observational studies, but no randomized controlled trials (RCTs) have been performed to date.

Patients and methods: A "tandem" endoscopy cross-over design. Participants will be randomized to endoscopy using mapping biopsies or AAC, in which dilute acetic acid is sprayed onto the surface of the esophagus, highlighting tissue through an whitening reaction and enhancing visibility of areas with cellular changes for biopsy. After 4 to 10 weeks, participants will undergo a repeat endoscopy, using the second method. Rates of recruitment and retention will be assessed, in addition to the estimated dysplasia detection rate, effectiveness of the endoscopist training program, and rates of adverse events (AEs). Qualitative interviews will explore participant and endoscopist acceptability of study design and delivery, and the acceptability of switching endoscopic techniques for Barrett's surveillance.

Results: Endoscopists' ability to diagnose dysplasia in Barrett's esophagus can be improved. AAC may offer a simple, universally applicable, easily-acquired technique to improve detection, affording patients earlier diagnosis and treatment, reducing endoscopy time and pathology costs. The ABBA study will determine whether a crossover "tandem" endoscopy design is feasible and acceptable to patients and clinicians and gather outcome data to power a definitive trial.

Conflict of interest statement

Competing interests None. The ABBA study is funded by the National Institute for Health Research, Research for Patient Benefit (Project Number PB-PG-1013-32045).

Figures

Fig.1 a
Fig.1 a
Barrettʼs neoplasia seen in white light.bSame area after acetic acid dye-spray – note early loss of acetowhitening.
Fig. 2
Fig. 2
Study design for participants.
Fig. 3
Fig. 3
Study timeline.

References

    1. Bhat S, Coleman H G, Yousef F et al.Risk of malignant progression in Barrettʼs oesophagus: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–1057.
    1. Jankowski J A.Progression to cancer and risk factorsIn: Guidelines for the diagnosis and management of Barrett’s columnar-lined oesophagus. A Report of the Working Party of the British Society of Gastroenterology.200521–23.
    1. Office for National Statistics Cancer Statistics registrations. Registrations of cancer diagnosed in 2008. England: Series MB1 2010 Dec: ISSN 0143– 4829
    1. Office for National Statistics (ONS) . Statistical Bulletin Cancer survival in England: Patients diagnosed 2005 – 2009 and followed up to 2010 – 2011
    1. Fitzgerald R C, Di Pietro M, Ragunath K et al.Guidelines on the Diagnosis and Management of Barrett’s Esophagus. Gut. 2014;63:7–42.
    1. Nilsson J, Skobe V, Johansson J et al.Screening for esophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the esophagus. Scand J Gastroenterol. 2000;35:10–16.
    1. Peters J H Clark GWB, Ireland A P et al.Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108:813–822.
    1. Pech O, Gossner L, Manner H et al.Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy. 2007;39:588–593.
    1. Kariv R, Plesec T P, Goldblum J R et al.The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than less-invasive surveillance protocol. Clin Gastroenterol Hepatol. 2009;7:653–658.
    1. Peters F P, Curvers W L, Rosmolen W D et al.Surveillance history of endoscopically treated patients with early Barrettʼs neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus. 2008;21:475–479.
    1. Garside R, Pitt M, Somerville M et al.Surveillance of Barrett’s esophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Tech Assess. 2006;10:No. 8.
    1. Sharma P, Weston A, Topalovski M et al.Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s esophagus. Gut. 2003;52:24–27.
    1. Gossner L, May A, Pech O et al.Chromoendoscopy for detection of dysplasia or mucosal cancer in Barrett’s esophagus. Gastrointest Endosc. 2000:A3537.
    1. Fortun P J, Anagnostopoulos G K, Kaye P et al.Acetic acid enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett’s esophagus. Aliment Pharmacol Ther. 2006;23:735–742.
    1. Wolfsen H C, Crook J E, Krishna M et al.Prospective, controlled tandem endoscopy study of narrow band imaging for dysplasia in Barrett’s esophagus. Gastroenterology. 2008;135:24–31.
    1. Georgakoudi I, Jacobson B C, Van Dam J et al.Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2001;120:1620–1629.
    1. Curvers W L, Alvarez Herrero L, Wallace M B et al.Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett’s esophagus. Gastroenterology. 2010;139:1106–1114.
    1. Chedgy F JQ, Kandiah K, Barr H et al.Development and validation of a training module on the use of acetic acid for the detection of Barrett’s neoplasia. Endoscopy. 2017;49:121–129.
    1. Longcroft-Wheaton G, Brown J, Basford P et al.Duration of acetowhitening as a novel objective tool for diagnosing high risk neoplasia in Barrett’s esophagus: a prospective cohort trial. Endoscopy. 2013;45:426–432.
    1. Longcroft-Wheaton G, Duku M, Mead R et al.Acetic acid spray is an effective tool for the endoscopic detection of neoplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2010;8:843–847.
    1. Pohl J, Pech O, May A et al.Incidence of macroscopically occult neoplasias in Barrett’s esophagus: are random biopsies dispensable in the era of advanced endoscopic imaging? Am J Gastroenterol. 2010;105:2350–2356.
    1. Bhandari P, Kandaswamy P, Cowlishaw D et al.Acetic acid-enhanced chromoendoscopy is more cost-effective than protocol-guided biopsies in a high-risk Barrett’s population. Dis Esophagus. 2012;25:386–392.
    1. Tholoor S, Bhattacharyya R, Tsagkournis O et al.Acetic acid chromoendoscopy in Barrettʼs esophagus surveillance is superior to the standardized random biopsy protocol: results from a large cohort study (with video) Gastrointest Endosc. 2014;80:417–424.
    1. Kandiah K, Chedgy F JQ, Subramaniam S et al.International development and validation of a classification system for the identification of Barrett's neoplasia using acetic acid chromoendoscopy: the Portsmouth acetic acid classification (PREDICT) Gut. 2017 doi: 10.1136/gutjnl-2017-314512.
    1. Sharma P, Dent J, Armstrong D et al.The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterol. 2006;131:1392–1399.
    1. Participants in the Paris Workshop . The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon. Gastrointest Endosc. 2012;58:S3–S43.
    1. Good clinical practice National Institute for Health Research; Available at(Accessed September 28, 2017)
    1. Subramanian V, Mannath J, Ragunath K et al.Meta-analysis: the diagnostic yield of chromoendoscopy for detecting dysplasia in patients with colonic inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:304–312.
    1. Lieberman D, Brill J, Canto M et al.Management of diminutive colon polyps based on endoluminal imaging. Clin Gastroenterol Hepatol. 2015;13:1860–1866.
    1. Schachschal G, Mayr M, Treszl A et al.Endoscopic versus histological characterisation of polyps during screening colonoscopy. Gut. 2014;63:458–65.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit